Spero Therapeutics (SPRO) Competitors $1.94 -0.03 (-1.52%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 09/25/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. RGNX, ITOS, CRVS, ZYBT, PRTA, ALMS, ZVRA, ETHZ, EOLS, and INBXShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include REGENXBIO (RGNX), iTeos Therapeutics (ITOS), Corvus Pharmaceuticals (CRVS), Zhengye Biotechnology (ZYBT), Prothena (PRTA), Alumis (ALMS), Zevra Therapeutics (ZVRA), Flag Ship Acquisition (ETHZ), Evolus (EOLS), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors REGENXBIO iTeos Therapeutics Corvus Pharmaceuticals Zhengye Biotechnology Prothena Alumis Zevra Therapeutics Flag Ship Acquisition Evolus Inhibrx Biosciences REGENXBIO (NASDAQ:RGNX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Do institutionals and insiders have more ownership in RGNX or SPRO? 88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to RGNX or SPRO? In the previous week, REGENXBIO and REGENXBIO both had 1 articles in the media. Spero Therapeutics' average media sentiment score of 1.91 beat REGENXBIO's score of 1.28 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment REGENXBIO Positive Spero Therapeutics Very Positive Which has more risk and volatility, RGNX or SPRO? REGENXBIO has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Is RGNX or SPRO more profitable? Spero Therapeutics has a net margin of -110.35% compared to REGENXBIO's net margin of -112.70%. REGENXBIO's return on equity of -66.95% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-112.70% -66.95% -34.14% Spero Therapeutics -110.35%-120.27%-55.61% Which has better earnings & valuation, RGNX or SPRO? Spero Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$83.33M5.67-$227.10M-$3.44-2.72Spero Therapeutics$47.98M2.28-$68.57M-$0.98-1.98 Do analysts rate RGNX or SPRO? REGENXBIO currently has a consensus target price of $28.38, suggesting a potential upside of 203.15%. Spero Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 157.73%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts plainly believe REGENXBIO is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryREGENXBIO beats Spero Therapeutics on 9 of the 15 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.86M$3.13B$5.74B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-1.9820.6375.7726.11Price / Sales2.28442.69544.59124.93Price / CashN/A44.6737.5461.24Price / Book2.289.6212.876.30Net Income-$68.57M-$52.73M$3.29B$271.03M7 Day Performance-3.00%1.81%0.26%-0.14%1 Month Performance4.86%5.50%2.85%5.82%1 Year Performance51.56%18.12%65.65%27.63% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.333 of 5 stars$1.94-1.5%$5.00+157.7%+51.6%$110.86M$47.98M-1.98150Positive NewsRGNXREGENXBIO4.6209 of 5 stars$9.06+1.9%$28.38+213.2%-13.6%$449.07M$83.33M-2.63370Positive NewsITOSiTeos Therapeutics3.2495 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsCRVSCorvus Pharmaceuticals2.2488 of 5 stars$6.04+2.9%$13.00+115.2%+27.1%$437.40MN/A-5.9830ZYBTZhengye BiotechnologyN/A$8.73-5.4%N/AN/A$435.35M$25.53M0.00278Gap UpPRTAProthena2.9834 of 5 stars$8.29+2.7%$19.75+138.2%-54.2%$434.41M$135.16M-1.47130Positive NewsALMSAlumis3.468 of 5 stars$4.15-0.5%$20.17+385.9%-65.3%$433.95MN/A0.00N/APositive NewsZVRAZevra Therapeutics2.7396 of 5 stars$7.95+3.7%$23.71+198.3%+26.1%$430.56M$23.61M-37.8620News CoverageOptions VolumeGap UpETHZFlag Ship AcquisitionN/A$2.40-5.1%N/AN/A$416.01MN/A-0.167Options VolumeGap UpEOLSEvolus4.0144 of 5 stars$6.31+0.3%$21.25+236.8%-62.8%$406.87M$266.27M-6.44170INBXInhibrx Biosciences1.0542 of 5 stars$27.12-1.7%N/A+106.5%$399.80M$200K-2.56166Positive News Related Companies and Tools Related Companies REGENXBIO Alternatives iTeos Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Zhengye Biotechnology Alternatives Prothena Alternatives Alumis Alternatives Zevra Therapeutics Alternatives Flag Ship Acquisition Alternatives Evolus Alternatives Inhibrx Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
